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Introduction and objective:

Long-term follow up of meningiomas has demonstrated recurrence rates of
up to 60% after 15 years. There is limited data available to guide the
management of recurrent and previously radiated skull base meningiomas
and challenges related to salvage surgery, re-irradiation and lack of clear
systemic therapy strategies remain. In this study, we analyzed data from
our experience with recurrent and previously radiated meningiomas to
assess the impact of salvage surgery and re-irradiation on PFS.

As seen in Table 2, patients with WHO grade 1 meningiomas who
underwent a STR had a 3.4-fold increase of disease progression
compared to patients where GTR was achieved (HR 3.38; 95% CI,
1.268-9.03; p=.0189) (Figure 2, D). For WHO grade 2 and 3 patients
however, EOR was not associated with differences in PFS (Figure 3, B
and D).

Table 2. Univariate Analysis of prognostic factors affecting PFS
UNIVARIATE ANALYSIS
Patient demographics
Age

KPS
Gender

Methods:

Tumor features

A retrospective cohort study of 48 patients with recurrent and previously
radiated meningiomas who were treated between 1995 and 2021 was
conducted. Data were extracted from medical records and include clinical,
radiologic, and pathologic reports. Patients were clustered according to
WHO grades. We analyzed the complications related to re-irradiation and
salvage surgery and the impact of different treatment modalities on PFS
using Cox proportional hazard ratios.

<60 years-old
≥60 years-old
KPS 90-100
KPS 60-80
Female
Male

Ref
1.68
Ref
2.61
Ref
1.288

Ref
1.156-2.443
Ref
1.510-4.50
Ref
0.8564-1.938
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11
26
7
15
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0.0025
˂0.0001
0.971

-

-

-

0.2535

P-Value

AF/MF/PF/Combined

Form

Globoid
En-Plaque

Ref
1.001

Ref
0.7012-1.429

12
20

0.1968

WHO grade

WHO 1
WHO 2
WHO 3

Ref
1.972
3.563

Ref
1.269-3.067
1.628-7.798

30
12
6

0.0002
˂0.0001

KI-67

KI-67 0-9%
KI-67 10-19%
KI-67 ≥20%

Ref
2.285
3.426

Ref
1.249-4.178
1.771-6.628

51
12
6

0.003
˂0.0001

Ref
0.8507

Ref
0.5280-1.371

28
36

0.483

Ref

Ref

23

-

-

28
32
14.5

0.162

Ref

Ref

9

-

0.365
0.457
-

0.175-0.757
0.218-0.959
-

41
22
18

0.0008
0.0238
-

Ref

Ref

5.5

-

SX + reRT
reRT

0.653
0.276

0.184-2.32
0.078-0.975

7
14

0.468
0.0028

EOR in WHO I

GTR
STR +/- reRT

Ref
0.2760

Ref
0.1272-0.5987

123
15

0.0087

EOR in WHO II

GTR +/- reRT2
STR +/- reRT3

Ref
0.8919

Ref
0.4321-1.841

15
9

0.139

GTR +/- reRT
Ref
Ref
STR +/- reRT
1.649
0.5297-5.132
1Only 3 patients, unpowered for statistical purposes
2 GTR + reRT = RR 0.259, 95% CI 0.099-0.6747, p=.0048, Median PFS=27 months
3 STR + reRT= RR 0.316, 95% CI 0.1304-0.7682, p=.0029, Median PFS=52 months
Bold letters indicate statistical significance

5.5
7

0.299

Type of reRT

When looking at the impact of re-irradiation, WHO grade 3 patients who
were re-irradiated were significantly less likely to progress over the
course of the study (HR 0.27; 95% CI, 0.078-0.975; p=.0028) (Figure 3,
C). Furthermore, adjuvant re-irradiation of subtotally or totally resected
WHO grade 2 meningioma patients decreased the likelihood of disease
progression over the course of the study (HR 0.316; 95% CI, 0.13040.7682; p=.0029 for STR+RT and HR 0.259; 95% CI, 0.099-0.6747;
p=.0048 for GTR+RT). (Figure 3, A). Repeat radiation was not found to
be associated with improved PFS in WHO grade 1 meningioma patients
(Table 2).

CI (95%)

Location

Treatment Related Variables

Figure 2. A: Progression-free survival (PFS) according to WHO grades, asterisk indicates a
statistically significant difference (p=<.0001). B: PFS according to age, asterisk indicates a
statistically significant difference (p=.0025). C: PFS of WHO grade 1 radiated meningiomas by
different treatment modalities (p=.162), SX (surgery), reRT (re-irradiation). D: PFS of WHO
grade 1 radiated meningiomas by extent of resection (EOR) (p=.0087).
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Conclusion:

We presented a retrospective analysis with the largest cohort of radiated and
recurrent skull base meningiomas. According to our results, achieving GTR is
the best option for recurrent WHO grade 1 meningiomas, radiation is the best
option for WHO grade 3 meningiomas, and radiation appears to provide a
benefit in subtotally resected WHO grade 2 meningiomas. Reoperation for
recurrent skull base meningiomas is associated with a higher complication
rate. Further prospective studies are needed to validate our results.

Figure 1. Diagram outlining patient selection

Results:

• Patient Demographics and number of recurrences

Forty-eight patients (33 WHO grade 1; 11 WHO grade 2; and 4 WHO grade
3) were treated for 143 recurrences after their first radiation treatment.
Although patients with higher grade meningiomas seem to have lower KPS
at recurrence, there was no significant association between KPS and
recurrence rate (X2 [1, N = 143] =3.52, p=.06). The overall survival rate was
56.2% after a mean follow-up period of 12.4±7.6 years, with 21 patients
with stable disease and 6 patients in hospice. Twenty patients from our
cohort (41.6%) had histologic progression (Figure 1 and Table 1).
Table 1. Treatment Outcomes

Figure 3. A: Progression-free survival (PFS) of WHO grade 2 radiated meningiomas by different
treatment modalities, asterisk indicates a statistically significant difference (reRT alone vs SX
alone; p=.0238 and reRT+SX vs SX alone; p=.0008). B: PFS of WHO grade 2 radiated
meningiomas by extent of resection (EOR) (p=.139). C: PFS of WHO grade 3 radiated
meningiomas by different treatment modalities, asterisk indicates a statistically significant
difference (p=.0028). D: PFS of WHO grade 3 radiated meningiomas by EOR (p=.299).

Discussion:

• Treatment offered to recurrences

Surgery alone (SX) was the most frequent treatment offered for recurrences
in WHO grade 1 and WHO grade 2 patients (37% and 19.8%, respectively).
Patients with GTR had a median time to recurrence of 123, 15 and 6
months for WHO grade 1, WHO grade 2 and WHO grade 3, respectively.
Surgical procedures had a complication rate of 23.8% (20/84), and this rate
increased over time: 10% (1/10), 18.4% (7/38), 100% (1/1), 39.3% (11/28)
and 100% (1/1) for first, second, third, fourth and fifth surgeries,
respectively.
Re-irradiation therapy was administered for seventy-three recurrences. Reirradiation was used along the course of the disease one, two and three
time in 32 (66.7%), 13 (27%) and 3 patients (6.3%). Among them, 38 (52%)
patients received EBRT, and 35 (48%) patients received SRS, with different
doses.

• Analysis of Factors Associated with PFS

Upon conducting univariate log-rank and Cox proportional hazards analysis,
we identified those variables that correlated with higher recurrence rate.
Among demographics variables, the 3-year PFS was 43.5%, 24.5% and
0%, for WHO grade 1, WHO grade 2 and WHO grade 3, respectively
(Figure 2, A).
Furthermore, age ≥60 years-old was associated with increased progression
(HR 1.68; 95% CI, 1.15-2.44; p=.0025) (Figure 2, B). As seen in Table 2,
patients with WHO grade 1 meningiomas who underwent a STR had a 3.4fold increase of disease progression compared to patients where GTR was
achieved (HR 3.38; 95% CI, 1.268-9.03; p=.0189) (Figure 2, D). For WHO
grade 2 and 3 patients however, EOR was not associated with differences in
PFS (Figure 3, B and D).
Furthermore, age ≥60 years-old was associated with increased progression
(HR 1.68; 95% CI, 1.15-2.44; p=.0025) (Figure 2, B).

To our knowledge, this is the largest reported cohort of post-radiation
recurrent skull base meningiomas summarizing the impact of salvage
surgery and repeat radiation on tumor control rates. The management of
post-radiation recurrence is not clear, but the decision should consider the
WHO grading, along with the multidisciplinary treatments available.
For WHO 1 meningiomas, despite the challenges associated with
previous radiation, we found a clear benefit of GTR over STR alone or
combined with RT. The impact of EOR on outcomes for WHO grade 2
meningiomas remains unclear and is even less effective in malignant
meningiomas. One hypothesis to explain the lack of correlation between
EOR and PFS could be the more aggressive behavior and a higher
proliferative index labeling in tumors that recur versus tumors that don’t
recur1. Furthermore, previous radiation might be a risk factor to increase
the aggressiveness of the tumor2.
This study also helps elucidate the potential role of re-irradiation with
recurrent skull base meningiomas. In our cohort, there were no
associated improvements in PFS with re-irradiation of grade 1
meningiomas. Conversely, the role of radiation seems to be more
important for WHO 2 and WHO 3 meningiomas. Indeed, we found an
improvement in PFS for re-irradiated WHO grade 2 meningiomas, but this
finding is opposed to other authors3. Nevertheless, it is important to
highlight that our patient cohort consisted exclusively of skull base
meningiomas, which have a different genomic signature than convexity
meningiomas and have different biological and clinical behavior4. Although
survival and tumor control are poor in WHO grade 3 meningiomas, there
is a consensus on the beneficial effect of radiation, irrespective of the
EOR5, and in our cohort of anaplastic meningiomas, re-irradiation
provided a PFS benefit when compared with surgery alone,
demonstrating that salvage RT still has a survival impact in already
radiated recurrences. Among demographic variables, age over 60 and
KPS ≤ 70 were predictors of unfavorable results that have been seen in
other studies6. To resume, we propose the following treatment algorithm
according to our results and the literature reported (Figure 4).

Figure 4. Diagram outlining proposed treatment algorithm for recurrent and radiated skull base
meningiomas
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